Burjeel Holdings to revolutionize cancer care in MENA with 90% cheaper CAR-T therapy
Abu Dhabi: In a groundbreaking move set to transform cancer treatment access across MENA, Burjeel Holdings has partnered with U.S.-based non-profit Caring Cross to locally manufacture CAR-T cell therapies at up to 90% less than current international costs. Caring Cross will support Burjeel Holdings with the necessary technology, materials, and specialized training to establish a local ecosystem for manufacturing CAR-T therapies, as well as providing lentiviral vectors essential for clinical development. The collaboration was announced at Abu Dhabi Global Health Week in the presence of Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings.
CAR-T therapies, which reprogram a patient's immune cells to attack cancer cells, have shown remarkable success in treating certain blood cancers like leukemia and lymphoma. However, with costs ranging from US$350,000 to over $1 million in global markets, access remains severely restricted. The partnership seeks to dismantle this barrier by enabling the production of CAR-T therapies at a fraction of the current price, making these treatments accessible to a vastly broader patient population in MENA and beyond.
Enhancing Access to Life-Saving Cancer Care
The collaboration will position Burjeel Holdings as a regional hub for advanced cell and gene therapies. By enabling local, point-of-care production of patient-specific therapies, the initiative will expand the reach of these therapies to underserved populations across the MENA region. The first phase of the program will focus on CAR-T therapies for leukemia and lymphoma, with plans to explore treatments for other diseases, including HIV, in the future.
'We are honored to partner with Caring Cross, whose expertise in CAR-T cell therapy production technology will enable us to provide affordable, life-saving treatments to our communities and beyond. This partnership is a pivotal step in our commitment to advancing medical innovation and expanding access to critical healthcare services,' said John Sunil, Group CEO of Burjeel Holdings.
'We are excited to partner with Burjeel Holdings to improve access to CAR-T cell and other ATMPs for patients across their hospital networks in the MENA region,' said Boro Dropulić, Executive Director of Caring Cross. 'This collaboration advances our mission to make these groundbreaking treatments accessible and affordable around the world. By combining our innovative technologies with Burjeel Holdings hospital network and infrastructure, we intend to significantly improve patient access with a sustainable and cost-effective model.'
Building Local Capabilities and Expanding Impact
This initiative reflects Burjeel Holdings' broader mission to expand access to high-quality healthcare in regions that need it most. The partnership will focus on training and developing local healthcare providers, ensuring the sustainable and scalable delivery of CAR-T therapies across MENA, India, and globally.
'Our collaboration is operating at the cutting edge of medical innovation, opening doors to biological therapies not just in MENA, but also in emerging markets like India and other parts of Asia. This is a monumental stride in enhancing access to cancer treatments and addressing the escalating need for advanced healthcare globally,' said Dr. Ajlan Al Zaki, Director of the Hematology Oncology & Cellular Therapy Center at Burjeel Hospital Abu Dhabi.
This partnership reinforces Burjeel Holdings' commitment to transforming the healthcare landscape in MENA and beyond, offering hope and tangible solutions to millions of patients who previously lacked access to life-saving treatments.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
an hour ago
- Zawya
Emerging markets ‘are poised to keep outperforming'
The outlook for emerging markets has stabilised in response to clearer US trade arrangements and persistent US dollar weakness, which are expected to resume, says the latest CIO Office Viewpoint from Lombard Odier. While US tariffs may weigh more on economies in the next few months, it sees solid earnings growth and a gradual rebound beginning in the last quarter of 2025, write Dr. Luca Bindelli, Head of Investment Strategy and Patrick Kellenberger, Emerging Market Equities Strategist, and Patrick Kellenberger, Emerging Market Equities Strategist. The US dollar's loss of momentum this year has provided a relief for many key emerging markets. Interest rate differentials, fiscal dynamics, and trust in institutional quality assets are all shifting in response to recent US policies. Lower valuations for EM equities compared with developed markets makes them attractive while in fixed income, higher-than-average yields favour EM hard currency bonds. In spite of the anticipated tariff-triggered economic slowdown in the third quarter of 2025, trade policy uncertainties are fading. Most emerging markets have also refrained from retaliating against the US measures, limiting the fallout from tariffs on their consumers and industries from price shocks. The impact of President Trump's country-specific tariffs, announced on August 1, may be lower if product or sector exemptions are factored in. For now, the US's average effective tariff has now risen from 2.4% in early 2024 to an estimated 16.5% today. In relative terms, US trade tariffs have not been applied more harshly to emerging markets. This leaves them no worse off, and sometimes with better trading conditions than economies including Europe, Canada, or Japan. In addition, the US and China have extended a 90-day truce for the second time. Both countries appear keen to avoid new provocations. The US has loosened export controls on cutting-edge AI chips, and China has not, so far, limited access to its refined rare earths, a market that it dominates. More broadly, US tariff rates on other EMs are now mostly known, and lower than first threatened. For Taiwan and South Korea, two key markets for the global economy, US tariffs are set at 20% and 15%, respectively. There may also be exemptions for strategically important semiconductors in return for investments by Taiwanese and South Korean chipmakers into the US. US dollar weakness ahead While the dollar has stabilised in recent weeks, the report sees further weakness ahead and has shifted its view on the currency from neutral to negative. 'With US inflation ticking slightly higher and companies neither hiring nor firing, market consensus is moving closer to our expectation for three interest rate cuts from the Federal Reserve before the year-end. For global investors, lower US rates will erode the dollar's yield advantage. Moreover, historically the US dollar also tended to weaken further in phases of increasing or elevated 'term premium', or the additional compensation for owning longer maturity bonds. Indeed, while we expect US long-term rates to moderate over time, we still expect the term premium to remain high in light of US fiscal deficit widening. As a result, we anticipate reduced demand for the US currency, while other major central banks and emerging markets are either seeing rates stabilise or fall only modestly, albeit from double-digit levels in Latin America (Brazil),' it says. Relative yield developments will therefore be detrimental to the USD. Also undermining the need for dollars are falling hedging costs associated with lower US policy rates and less extreme short investor positioning. Another Chinese tariff reprieve can also support EM currency sentiment in the near term, and we have adopted a more positive view on EM currencies. Investors may also be reassured by political conditions in many markets. In some Eastern Europe, Middle Eastern, and Latin American economies, there is a shift towards more business-friendly policy. In South Korea, the peaceful transfer of power to the centre-left opposition party in June led to strong market outperformance. Latin America will hold a series of important national elections, where voter fatigue with incumbents may propel more market friendly candidates to power. Alternative flow Starting in April with the US tariff policy announcements, international investors began looking for alternatives to the US market. Still, EM assets remain under-owned in the developed world. In 2017, a recent high, EM assets accounted for 7% of European and North American investors' portfolios, and that figure stands at 5.1% today. How are emerging equity markets expected to perform? First, and in relation to the US dollar outlook described above, a depreciating dollar (and appreciating EM currencies) has generally coincided with EM equity inflows and positive equity performance. Relative to developed market stocks, they offer a valuation discount that is currently around 35% in forward 12-month price-to-earnings terms. This should support inflows as investors are returning to emerging markets in a search for diversification and growth opportunities. Indeed, while we anticipate a slowdown in EM earnings in the third quarter, these should reaccelerate towards the end of the year and continue to provide a source of support to the regional equity outlook, also on a relative basis. We see a good chance that the 24 constituents of the MSCI emerging market index continue to outperform developed markets in 2026. We increased our exposure to EM equities in May, once US trade policy started to moderate from initial levels and expect all major EMs to post solid returns over the next year. China may deliver more attractive earnings, thanks to recent policy initiatives and a more liberal stance on the private sector. Taiwan's market looks expensive, but EPS (earnings per share) growth is being driven by AI developments. In Brazil, we see earnings challenged by lower commodity prices, but dividend yields look attractive. We also like South Korean stocks, where corporate governance reforms could lift valuations and robust earnings growth is supported by computer memory/AI demand. In India, and despite the near-term setback from tariffs imposed by the Trump administration in retaliation for Russian oil imports, we expect the situation to stabilise eventually, possibly with progress in Russia/Ukraine peace talks. We see the stock market re-accelerating after a cyclical slowdown reflecting improving domestic demand, and with low inflation, there is scope for interest rate cuts. In fixed income, we have increased our exposure to emerging market hard currency bonds and reduced our positions in global government bonds. Despite year-to-date spreads narrowing, EM hard currency yields remain higher than their historical averages and provide more attractive yields compared to other fixed income segments. In particular, EM bonds offer similar yields to those available in the comparatively riskier credit segments. Moreover, we expect EM spreads to remain relatively more stable as the EM economic outlook becomes more resilient. Finally, and with looser Fed monetary policy expected soon, short-dated US Treasury yields should decline more quickly than longer-dated maturities, generating a so-called steepening yield curve. This development would typically allow EM debt to continue to outperform US Treasuries. - TradeArabia News Service Copyright 2025 Al Hilal Publishing and Marketing Group Provided by SyndiGate Media Inc. (
Khaleej Times
11 hours ago
- Khaleej Times
S&P affirms 'AA+' credit rating for US, cites impact of tariff revenue
S&P Global on Monday affirmed its "AA+" credit rating on the US, saying the revenue from President Donald Trump's tariffs will offset the fiscal hit from his massive tax-cut and spending bill. Trump signed the "One Big Beautiful Bill Act" into law in July after it was passed by the Republican-controlled Congress. The bill, which delivered new tax breaks, also made Trump's 2017 tax cuts permanent. "Amid the rise in effective tariff rates, we expect meaningful tariff revenue to generally offset weaker fiscal outcomes that might otherwise be associated with the recent fiscal legislation, which contains both cuts and increases in tax and spending," S&P said in a statement. "At this time, it appears that meaningful tariff revenue has the potential to offset the deficit-raising aspects of the recent budget legislation." The U.S. reported a $21 billion jump in customs duty collections from Trump's tariffs in July, but the government budget deficit still grew nearly 20% in the same month to $291 billion. Interest on the public debt also continued to grow, hitting $1.013 trillion in the first 10 months of the fiscal year, an increase of 6%, or $57 billion, over the prior-year period due to slightly higher interest rates and increased debt levels. Since returning to power in January this year, Trump has launched a global trade war with a range of tariffs that have targeted individual products and countries. The Republican president has set a baseline tariff of 10% on all imports to the U.S., as well as additional duties on some items and trading partners. IMPACT OF TARIFFS S&P, which became the first ratings agency to cut the pristine U.S. government rating in 2011, said the outlook on the U.S. rating remains stable. The ratings agency said it expects the Federal Reserve, which Trump has criticized this year for not cutting interest rates, "to navigate the challenges of lowering domestic inflation and addressing financial market vulnerabilities." It projected the country's general government deficit to average 6.0% of GDP during the 2025-2028 period, down from 7.5% in 2024 and from an average 9.8% of GDP in 2020-2023. S&P said it could lower the rating over the next two to three years if already high deficits increase. "The ratings could also come under pressure if political developments weigh on the strength of American institutions and the effectiveness of long-term policymaking or independence of the Federal Reserve," it said. SP, however, said it could raise the U.S. rating in the event of sustained economic growth and adjustments to the U.S. fiscal profile that would diminish recent increases in the country's debt burden. There was no reaction in markets on Tuesday to SP's credit rating affirmation, which follows a U.S. sovereign credit downgrade by Moody's in May, when that ratings agency cut the triple-A U.S. rating by one notch, citing rising debt levels. The U.S. national debt load surged above a record $37 trillion last week. James Ragan, co-chief investment officer and director of investment management research at D.A. Davidson, said the SP rating affirmation was an acknowledgment of the meaningful tariff revenue generated so far. "That's all good revenue (coming) in, but that's also a drag on the economy, so I think we don't know the impact of that going forward," he said.
The National
15 hours ago
- The National
India needs to find its own ‘Trump whisperers' to deal with the US tariff threat
The threat of up to 50 per cent US tariffs on goods from India, which emerged from the White House over the past month, struck many as a bolt seemingly out of the blue. Indian Prime Minister Narendra Modi had had a good visit to Washington in February, and a detailed trade deal between Washington and New Delhi seemed all set for approval at the end of this month. While India will probably avoid the worst-case outcome, the level of surprise indicates that New Delhi lacks high-level advocates in Washington with the inside track. As a result, it is still struggling to grasp how US President Donald Trump makes decisions, or how he views both trade and the Indo-US equation. Until those inter-linked problems are sorted out, bilateral relations will continue to bounce between the highs of periodic direct contact by the two national leaders, and regular lows in between. India's diplomatic and business communities continue to wonder how things went so wrong between the two governments in recent months. The answer to this question lies in New Delhi's struggle to adapt to Mr Trump's commercial (rather than diplomatic) approach to dealmaking. The tariff threats to India come from two directions: the Russia-Ukraine war and the emergence of competition – as opposed to co-operation – between major trading powers facing the threat of tariffs from Washington. The war in Ukraine is the more volatile of the two factors, with the Trump administration's policy veering from Moscow's point of view, then to that of Kyiv and Brussels, and now back to Moscow's following the US-Russia summit in Alaska last Friday. This latest swing is good news for New Delhi, as the threat of secondary sanctions for buying Russian oil is likely to recede at least temporarily. But even if (or more likely when) the pendulum swings again, it is unlikely that the US will be maximalist in its demands. Any rapid and major change in Indian oil purchases would put strains on global oil supply and send prices shooting up for American voters, something that no administration wants to see. The battle between the EU and UK on the one hand, and Russia on the other, to influence Mr Trump on the war in Ukraine also provides an essential window into the challenges of diplomacy with the administration. Much has been made in commentary about the importance of top-level chemistry, and the natural advantage of strong leaders such as Russian President Vladimir Putin winning Mr Trump's respect and agreement. However, Russia's example goes to show why this just isn't enough. Mr Putin's ability to effectively communicate Russia's perspective is extremely powerful. But the lack of any other interlocutors who can engage with Mr Trump as persuasively means that Moscow struggles to build momentum. In contrast, the EU and UK have found a range of 'Trump whisperers', people below the head-of-state level who understand the US President. It is these contacts who have managed to stay appraised of Mr Trump's ever-shifting priorities and perspectives and convince him of the relevance of their positions to those priorities. Until India can find its own Trump whisperers, the positive, can-do Trump-Modi personal equation will not be enough to keep the bilateral relationship on the rails. The other half of the tariff threat is closely tied to this problem. Mr Modi's productive meeting with Mr Trump in February gave India's notoriously tough negotiators a sense of what it would take to craft an agreement that would satisfy both sides. But one of the Trump administration's greatest successes is that it has created competition rather than co-operation between countries facing the threat of US tariffs. Over the course of the summer, the larger trade partners of the US – led by the EU and UK – showed a new willingness to cross their own previous red lines to make deals with Washington. Mr Trump seems to regard it as axiomatic that these developments shifted the baseline of expectations for all others who followed. In this view, it would be up to India (currently only the US's 10th-largest trade partner) to try to improve its offer and match the depth of concessions granted by the larger US trade partners. Despite all this, India and the EU find themselves in a similar boat. The Trump administration does not view either entity to be dominant security actors in their regions (unlike say China, Russia or Israel). This magnifies his annoyance when they offer a narrative that contradicts his own – for example, the EU's constant reminders that Russia is the aggressor in the Ukraine war, or New Delhi's rejection of Mr Trump's claim that he mediated the end of the recent hostilities between itself and Pakistan earlier this year. Similarly, the US President's anger with European and Indian trade surpluses with Washington is complemented by a lack of fear over their economic advantage. In contrast, Mexico, China and Canada have greater political leverage than the EU or India that goes beyond the sheer volume of trade with the US. These exporters supply daily goods from food to energy and mid-to-low-range cars and phones that have a critical direct impact on the everyday lives of average American voters. Any trade war brings serious political costs for the Trump administration. Indian exports, on the other hand, range from engineering goods to gems and jewellery that do not carry the same risks. Neither do luxury European goods, whether cheese, wine or limousines. The one exception is India's supply of generic medications, which have become a cornerstone of American health care; a canny Mr Trump may extend a temporary waiver to generate pressure while avoiding backlash. In short, the strength of India's hand in dealing with the Trump administration is fundamentally different than it looked at the start of the US President's second term, when the new rules of the power game were just beginning to emerge. But on the other hand, the European experience suggests that even a so-so hand can be played to great advantage once those new power rules have been understood and applied.
